C4 Therapeutics, Inc. Depreciation
C4 Therapeutics, Inc. (CCCC) reported Depreciation of $336.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-11
- C4 Therapeutics, Inc. depreciation for the quarter ending 2026-06-30 was $336.00K, a 19.23% decline year-over-year.
- C4 Therapeutics, Inc. depreciation for the quarter ending 2026-03-31 was $360.00K, a 1.10% decline year-over-year.
- C4 Therapeutics, Inc. depreciation for the quarter ending 2025-12-31 was $377.00K, a 3.57% increase year-over-year.
- C4 Therapeutics, Inc. depreciation for the quarter ending 2025-09-30 was $384.00K, a 5.21% increase year-over-year.
- C4 Therapeutics, Inc. depreciation for fiscal 2025 was $1.54M, a 4.62% increase from fiscal 2024.
- C4 Therapeutics, Inc. depreciation for fiscal 2024 was $1.47M, a 6.65% decline from fiscal 2023.
- C4 Therapeutics, Inc. depreciation for fiscal 2023 was $1.58M, a 5.85% decline from fiscal 2022.
- C4 Therapeutics, Inc. depreciation for fiscal 2022 was $1.68M, a 12.33% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 3 month as first filed | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $336.00K 10-Q · filed 2026-08-11 | $696.00K 10-Q · filed 2026-08-11 | $1.07M derived: sum of 3 quarters · filed 2026-08-11 | $1.46M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $360.00K 10-Q · filed 2026-05-12 | $737.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.12M derived: sum of 3 quarters · filed 2026-05-12 | $1.54M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $377.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $761.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.18M derived: sum of 3 quarters · filed 2026-08-11 | $1.54M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $384.00K 10-Q · filed 2025-11-06 | $800.00K derived: sum of 2 quarters · filed 2026-08-11 | $1.16M 10-Q · filed 2025-11-06 | $1.53M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $416.00K 10-Q · filed 2026-08-11 | $780.00K 10-Q · filed 2026-08-11 | $1.14M derived: sum of 3 quarters · filed 2026-08-11 | $1.51M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $364.00K 10-Q · filed 2026-05-12 | $728.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.09M derived: sum of 3 quarters · filed 2026-05-12 | $1.39M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $364.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $729.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.02M derived: sum of 3 quarters · filed 2026-02-26 | $1.47M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $365.00K 10-Q · filed 2025-11-06 | $661.00K derived: sum of 2 quarters · filed 2025-11-06 | $1.11M 10-Q · filed 2025-11-06 | $1.16M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $296.00K 10-Q · filed 2025-08-07 | $744.00K 10-Q · filed 2025-08-07 | $799.00K derived: sum of 3 quarters · filed 2025-08-07 | $1.25M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $375.00K 10-Q · filed 2025-05-07 | $448.00K 10-Q · filed 2024-05-08 | $503.00K derived: sum of 2 quarters · filed 2025-05-07 | $950.00K derived: sum of 3 quarters · filed 2025-05-07 | $1.41M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $128.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $575.00K derived: sum of 2 quarters · filed 2025-02-27 | $1.03M derived: sum of 3 quarters · filed 2025-02-27 | $1.58M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $447.00K 10-Q · filed 2024-10-31 | $905.00K derived: sum of 2 quarters · filed 2024-10-31 | $1.45M 10-Q · filed 2024-10-31 | $1.97M derived: sum of 4 quarters · filed 2024-10-31 | |
| 2023-06-30 | $458.00K 10-Q · filed 2024-08-01 | $1.00M 10-Q · filed 2024-08-01 | $1.52M derived: sum of 3 quarters · filed 2024-08-01 | $1.94M derived: sum of 4 quarters · filed 2024-08-01 | |
| 2023-03-31 | $545.00K 10-Q · filed 2024-05-08 | $1.07M derived: sum of 2 quarters · filed 2024-05-08 | $1.48M derived: sum of 3 quarters · filed 2024-05-08 | $1.92M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2022-12-31 | $521.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $936.00K derived: sum of 2 quarters · filed 2024-02-22 | $1.37M derived: sum of 3 quarters · filed 2024-02-22 | $1.68M 10-K · filed 2024-02-22 | |
| 2022-09-30 | $415.00K 10-Q · filed 2023-11-01 | $850.00K derived: sum of 2 quarters · filed 2023-11-01 | $1.16M 10-Q · filed 2023-11-01 | $1.48M derived: sum of 4 quarters · filed 2023-11-01 | |
| 2022-06-30 | $435.00K 10-Q · filed 2023-08-08 | $740.00K 10-Q · filed 2023-08-08 | $1.06M derived: sum of 3 quarters · filed 2023-08-08 | $1.39M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | $305.00K 10-Q · filed 2023-05-04 | $628.00K derived: sum of 2 quarters · filed 2023-05-04 | $958.00K derived: sum of 3 quarters · filed 2023-05-04 | $1.35M derived: sum of 4 quarters · filed 2023-05-04 | |
| 2021-12-31 | $323.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $653.00K derived: sum of 2 quarters · filed 2023-02-23 | $1.04M derived: sum of 3 quarters · filed 2023-02-23 | $1.49M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $330.00K 10-Q · filed 2022-11-03 | $718.00K derived: sum of 2 quarters · filed 2022-11-03 | $1.17M 10-Q · filed 2022-11-03 | $1.53M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | $388.00K 10-Q · filed 2022-08-04 | $839.00K 10-Q · filed 2022-08-04 | $1.20M derived: sum of 3 quarters · filed 2022-08-04 | $1.62M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | $451.00K 10-Q · filed 2022-05-05 | $816.00K derived: sum of 2 quarters · filed 2022-05-05 | $1.24M derived: sum of 3 quarters · filed 2022-05-05 | $1.65M derived: sum of 4 quarters · filed 2022-05-05 | |
| 2020-12-31 | $365.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $785.00K derived: sum of 2 quarters · filed 2022-02-24 | $1.20M derived: sum of 3 quarters · filed 2022-02-24 | $1.62M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $420.00K 10-Q · filed 2021-11-10 | $836.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.25M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $416.00K 10-Q · filed 2021-08-11 | $832.00K 10-Q · filed 2021-08-11 | |||
| 2020-03-31 | $416.00K 10-Q · filed 2021-05-13 | ||||
| 2019-12-31 | $1.59M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |